During the past 30 years evidence has been accumulating which suggests that glucagon (the hyperglycemic-glycogenolytic factor of the pancreas) is a true hormone and that it is produced in the Islets of Langerhans (1, 2). Its purification and crystallization were finally accomplished in 1953 by Staub, Sinn, and Behrens (3). The crystalline material is a simple protein with a molecular weight of approximately 4,200 and an amino acid composition which differs in important ways from that of insulin (4). This establishes glucagon as an entity distinct from insulin.
of glucagon on liver phosphorylase adequately explains its well-known hyperglycemic-glycogenolytic action.
With respect to its role in carbohydrate metabolism, some investigators look upon glucagon as an insulin antagonist (1, 2, 7) while others consider it an insulin synergist (8, 9) . Still others are skeptical of its hormonal nature (10, 11) . In the present paper experiments are reported which indicate that glucagon, in addition to mobilizing liver glycogen, increases the peripheral utilization of glucose."
METHODS
Human experiments. Thirty-two male subjects (ages 21 to 47) considered normal with respect to carbohydrate metabolism were studied. All were hospital patients on high caloric and carbohydrate intakes for at least three I Glucose utilization is used to mean the disappearance of blood glucose. days before being studied. The test procedure was begun in the morning after a 14-hour fast. Soon after awakening the subjects were placed at bed rest for 30 to 60 minutes in the testing room before the experiment was begun. A 10 per cent solution of glucose was infused intravenously at a constant rate (250 to 370 mg.
per min. in different subjects) by means of a constant infusion pump (Bowman) for periods of 120 to 145 minutes. In 12 subjects glucagon2 (0.7 to 1.0 mg.) was added to the perfusate following an initial period of 40 to 60 minutes with glucose alone. In 12 subjects the glucose infusion rate was doubled after 50 minutes and after 90 minutes the initial rate was resumed in order to simulate the hyperglycemia caused by glucagon. Two subjects received glucose at a constant rate for 2 hours. The initial control data on 8 other subjects who subsequently received other hormones were also used in the analysis of data.
Glucose determinations (Nelson-Somogyi Method) (12) were done on venous (indwelling needle in antecubital vein) and capillary (finger) blood from the same arm at 5 or 10-minute intervals, using 0.2-ml. samples (30 to 40 samples from each subject). Venous samples were drawn without stasis and analyzed in duplicate. (The average difference between duplicate determinations was 2 per cent.) The antecubital vein carries venous drainage from the deep and superficial tissues of the forearm (13) (14) (15) , while capillary blood has the same glucose content as arterial blood (16) (17) (18) .
Sodium space was determined in 8 subjects receiving glucagon and 12 subjects receiving glucose alone using radiosodium (Na') which was added to the infusion fluid. Plasma samples (drawn along with samples for glucose determination) were assayed for radioactivity in a R-C Scientific scintillation well type counter. The method used to calculate sodium space by this technique will be described elsewhere (19 Blood samples were drawn without stasis from indwelling needles in the femoral artery and vein. Glucose determinations were done on 1-ml. (normal dogs) or 0.5-ml.
(depancreatized dogs) samples in duplicate.
RESULTS

Human experiments
Tables I, II, and III contain the arteriovenous glucose data from the 32 subjects. Two types of response to glucagon were observed. In 11 subjects, blood sugar fell after reaching a peak level, despite the constant infusion of glucagon (Figure 1-A) . In one subject the peak glucose levels persisted throughout the test period. In all subjects glucagon, in addition to producing a sharp rise in blood sugar levels resulted in a marked increase in arteriovenous (A-V) glucose differences. In the 12 subjects in whom the glucose infusion was doubled following the control period, the arterial glucose concentrations closely simulated those observed in the subjects receiving glucagon. However, the A-V glucose differences were much less (Figure 1-B increase in A-V glucose difference in the normal dog when given as a single injection or by continuous infusion (Figure 3) . Similar results were observed in the depancreatized animal (Figure 4) . As in the human, the increased A-V glucose differences persist after the disappearance of the hyperglycemia.
DISCUSSION
Previous work from this laboratory, using a single glucose injection technique, suggested that glucagon causes a marked increase in A-V glucose differences in man (21) . Recently, Van Itallie, Morgan, and Dotti (22) have reported experiments which support this finding. Both of these studies depended on the assumption that blood flow and A-V glucose differences remain constant from day to day in a given individual. Actually, blood flow and A-V glucose differences may vary considerably in a given individual from day to day (23, 24) . The present studies were designed to minimize these variables. Thus, both the control and hormone test periods were run in sequence within a 2%2-hour period under standardized basal conditions. Under these experimental conditions, the variations in A-V/A values observed during the control periods were not significant.4 This is good evidence that blood flow was essentially constant. Glucagon itself (unlike adrenalin) has no cardiovascular effects (1, 2) . Thus the A-V glucose differences observed in the present experiments may be considered proportional to glucose utilization in the forearm and hand.
The relationship of glucose utilization to the height of the arterial blood sugar is pertinent to this study, since glucagon causes a marked rise in arterial glucose concentration. The glucose infusion experiments indicate that peripheral utilization of glucose is proportional to arterial glucose levels in the range between 80 and 210 mg. per cent in agreement with previous work (16) (17) (18) . Glucagon results in significantly greater glucose utilization at comparably elevated glucose levels. These observations are of considerable importance from the standpoint of glucagon's potential role in the regulation of carbohydrate metabolism. They indicate that glucagon has two integrated actions; namely, the mobilization of liver glycogen and the enhancement of the peripheral utilization of glucose. The persistence of the peripheral effect beyond the disappearance of the hyperglycemia suggests that glucagon has a more prolonged action than hitherto believed. The occurrence of these two effects of glucagon in preliminary experiments in the depancreatized dog indicates that the effects are independent of insulin action.
There is some experimental evidence which suggests that pituitary growth hormone causes the release of glucagon and that part of the diabetogenic action of the former is due to the released glucagon (1, 2 Studies on the effect of glucagon on blood glucose utilization in normal men using a constant glucose infusion technique have been presented. They show that glucagon causes a highly significant increase in the peripheral utilization of glucose which persists after the disappearance of the hyperglycemia. This increased glucose utilization is significantly greater than that observed with the hyperglycemia produced by glucose alone. The findings suggest that glucagon may fulfil a dual role in carbohydrate metabolism by producing hyperglycemia through mobilization of liver glycogen and concomitantly increasing the peripheral utilization of blood glucose. They also indicate that glucagon has a more prolonged action than previously thought.
Preliminary studies in normal and depancreatized dogs are also reported. Both groups of animals respond to glucagon in the same way as the normal human subject. These experiments indicate that the enhancing action of glucagon on the peripheral utilization of glucose does not depend upon a release of insulin.
APPENDIX
In the normal dog (18) it has been shown that the peripheral utilization of glucose (P) is a linear function of arterial glucose concentration (A). Therefore:
where k is the proportionality constant. At any time t: P = R (A-V), (2) where R is the blood flow and V is the venous blood glucose concentration. If (1) and (2) are equated, it may be shown that:
A where K is a function of the specific rate constant of peripheral glucose utilization, the volume of glucose distribution and peripheral blood flow. If blood flow and glucose distribution remain constant, then A -V/A must remain constant unless the rate constant of peripheral glucose utilization changes.
